Sapience Therapeutics Presents Positive Clinical and Biomarker Data from ST101 Phase 2 Study in GBM at ASCO 2024 in Oral Presentation

-Data demonstrates durable responses across 3 cohorts of patients with recurrent and newly diagnosed GBM- -Data supports continued clinical development of ST101 as a backbone treatment in combination with standard-of-care and immune-oncology agents- TARRYTOWN, N.Y., June 1, 2024…